Westpac Banking Corp Invests $6.98 Million in Cardinal Health, Inc. $CAH

Westpac Banking Corp purchased a new stake in Cardinal Health, Inc. (NYSE:CAH) in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 29,384 shares of the company’s stock, valued at approximately $6,980,000.

Several other hedge funds also recently modified their holdings of the company. Investors Research Corp acquired a new position in Cardinal Health in the 2nd quarter worth about $29,000. University of Texas Texas AM Investment Management Co. acquired a new stake in shares of Cardinal Health during the fourth quarter valued at about $26,000. Allied Private Wealth LLC acquired a new stake in shares of Cardinal Health during the second quarter valued at about $30,000. Bank of Jackson Hole Trust bought a new stake in shares of Cardinal Health during the fourth quarter worth about $27,000. Finally, Indiana Trust & Investment Management Co bought a new stake in shares of Cardinal Health during the first quarter worth about $29,000. Institutional investors and hedge funds own 87.17% of the company’s stock.

Key Cardinal Health News

Here are the key news stories impacting Cardinal Health this week:

• Positive Sentiment: Royal Bank of Canada initiated coverage with an “outperform” rating and a $276 price target, implying meaningful upside from recent trading levels. RBC cited Cardinal Health’s higher-margin services as a potential earnings-growth driver. RBC initiates coverage of Cardinal Health
• Positive Sentiment: Wall Street remains broadly constructive, with 16 analysts rating CAH a Buy and three assigning a Hold rating. The consensus rating is “Moderate Buy,” with an average price target of approximately $266.56. Zacks also identified Cardinal Health as a potentially attractive long-term value stock. Zacks value-stock analysis
• Positive Sentiment: Cardinal Health’s latest quarter delivered adjusted earnings per share of $2.91, well above the $2.42 consensus estimate, while revenue increased 5.8% year over year. Fiscal 2027 EPS guidance of $12.40–$12.60 supports the longer-term earnings case.
• Neutral Sentiment: The company declared a quarterly dividend of $0.5158 per share, equivalent to $2.06 annually and a yield of about 0.9%. The payout offers modest income support but is unlikely to be a major near-term catalyst.
• Negative Sentiment: Several executives sold sizable holdings around $235–$237 per share. CEO Jason Hollar sold 124,529 shares worth about $29.4 million, while other executive and insider sales—including those by Deborah Weitzman, Stephen Mason, Michelle Greene, Jessica Mayer and Mary Scherer—totaled roughly $20 million more. The concentrated selling and substantial reductions in insider ownership may encourage profit-taking concerns after CAH’s strong advance. Cardinal Health insider sales
• Negative Sentiment: Investors may also question the durability of the latest earnings beat because part of the improvement reportedly reflected a one-time tariff refund, potentially limiting the stock’s upside if recurring earnings growth does not match expectations. Cardinal Health earnings analysis

Insider Transactions at Cardinal Health

In related news, CEO Jason M. Hollar sold 80,000 shares of Cardinal Health stock in a transaction on Tuesday, August 18th. The shares were sold at an average price of $235.74, for a total transaction of $18,859,200.00. Following the completion of the transaction, the chief executive officer owned 235,132 shares of the company’s stock, valued at $55,430,017.68. This trade represents a 25.39% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Michelle D. Greene sold 11,650 shares of the business’s stock in a transaction on Tuesday, August 18th. The shares were sold at an average price of $235.72, for a total transaction of $2,746,138.00. Following the completion of the transaction, the insider owned 10,330 shares in the company, valued at approximately $2,434,987.60. The trade was a 53.00% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders have sold 210,271 shares of company stock worth $49,626,657. Company insiders own 0.12% of the company’s stock.

Cardinal Health Trading Up 0.4%

Shares of CAH stock opened at $229.48 on Friday. Cardinal Health, Inc. has a 1-year low of $145.87 and a 1-year high of $258.30. The stock has a market cap of $53.37 billion, a price-to-earnings ratio of 31.74, a PEG ratio of 1.22 and a beta of 0.49. The stock has a 50-day moving average of $232.02 and a 200-day moving average of $217.86.

Cardinal Health (NYSE:CAH) last posted its quarterly earnings data on Tuesday, August 11th. The company reported $2.91 EPS for the quarter, topping analysts’ consensus estimates of $2.42 by $0.49. Cardinal Health had a negative return on equity of 98.53% and a net margin of 0.67%.The company had revenue of $63.67 billion for the quarter, compared to analyst estimates of $65.15 billion. During the same period in the previous year, the firm earned $2.08 earnings per share. The firm’s quarterly revenue was up 5.8% on a year-over-year basis. Cardinal Health has set its FY 2027 guidance at 12.400-12.600 EPS. Sell-side analysts forecast that Cardinal Health, Inc. will post 12.54 earnings per share for the current year.

Cardinal Health Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, October 15th. Stockholders of record on Thursday, October 1st will be given a $0.5158 dividend. The ex-dividend date is Thursday, October 1st. This represents a $2.06 dividend on an annualized basis and a dividend yield of 0.9%. Cardinal Health’s payout ratio is 28.49%.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on the stock. UBS Group raised their price objective on shares of Cardinal Health from $274.00 to $280.00 and gave the company a “buy” rating in a report on Wednesday, August 12th. Weiss Ratings lowered shares of Cardinal Health from a “buy (b+)” rating to a “buy (b)” rating in a report on Wednesday. Evercore restated an “outperform” rating and issued a $270.00 price target on shares of Cardinal Health in a research report on Wednesday, August 12th. Citigroup raised their price target on shares of Cardinal Health from $265.00 to $280.00 and gave the company a “buy” rating in a research note on Wednesday, August 12th. Finally, JPMorgan Chase & Co. lifted their price target on shares of Cardinal Health from $215.00 to $260.00 and gave the stock a “neutral” rating in a report on Thursday, August 13th. Sixteen investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $266.56.

Cardinal Health Profile

Cardinal Health is a multinational healthcare services and products company headquartered in Dublin, Ohio. Tracing its roots to the early 1970s, the company has grown into a major provider of supply chain and distribution services for the healthcare sector. Cardinal Health operates across a range of service lines that support hospitals, health systems, pharmacies, physician offices and clinical laboratories.

The company’s core activities include the wholesale distribution of branded and generic pharmaceuticals, the supply and distribution of medical-surgical products, and the provision of logistics and inventory management solutions.